Metastatic Merkel Cell Carcinoma: Insights on the Clinical Application of Immune Checkpoint Inhibitors

Download All
This multifaceted program, which includes a module, interactive toxicity management algorithm tool, summary resource guide, and expert commentaries, equips clinicians with evidence-based insights on how to incorporate immune checkpoint inhibitors into clinical management of patients with metastatic Merkel cell carcinoma.
Shailender Bhatia, MD
Sandra P. D'Angelo, MD
Howard L. Kaufman, MD
Paul Nghiem, MD


In this commentary, Sandra P. D’Angelo, MD, highlights the practice-changing use of immune checkpoint inhibitor therapy for the treatment of patients with metastatic Merkel cell carcinoma.

Sandra P. D'Angelo, MD Released: November 30, 2016

In this commentary Shailender Bhatia, MD, shares his perspective on the unprecedented efficacy of immunotherapy in treating a patient with bulky metastatic MCC.

Shailender Bhatia, MD Released: February 27, 2017

In this commentary, Howard L. Kaufman, MD, highlights practice-changing clinical trial results on avelumab, the first FDA-approved treatment for metastatic Merkel cell carcinoma.

Howard L. Kaufman, MD Released: May 19, 2017

With avelumab now approved for MCC, what treatment options are available to patients not responding to checkpoint inhibitors? Read my thoughts on a promising new approach.

Paul Nghiem, MD Released: August 9, 2017
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)

This activity is supported by an educational grant from
Pfizer Inc.
Merck KGaA

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.